Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fingolimod 0.5 mg vs Gilenya in Healthy Fasting Subjects
NCT03757338Phase 1Completed
- Sponsor
- Asofarma
- Start
- Oct 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Asofarma. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve from time 0 to last quantifiable concentration at 72 hours and 1 more. Started Oct 2015; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03757338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757338.